Rezultati
eNauka >
Rezultati >
HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal j
| Naziv: | HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal j | Autori  : | Laeufle, Rita; ...; Andric, Zoran G   ; ...; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z; ...; (broj, koautora 16) |
Godina: | 2021 | Publikacija: | JOURNAL OF CLINICAL ONCOLOGY | ISSN: | 0732-183X Journal of Clinical Oncology Pretraži identifikator |
Tip rezultata: | Konferencijski rad | Kolacija: | vol. 39 br. 15 str. e16065-e16065 | DOI: | 10.1200/JCO.2021.39.15_suppl.e16065 | WoS-ID: | 000708120302003 | URI: | https://enauka.gov.rs/handle/123456789/802344 | Projekat: | Imugene Australia | Izvor metapodataka: | (Preuzeto iz Nasi u WoS) | M-kategorija: | Mp kategorija će biti prikazana naknadno. |
Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.